<DOC>
	<DOCNO>NCT02374099</DOCNO>
	<brief_summary>The purpose study Assess Efficacy Safety Epigenetic Modifying Effects CC-486 ( Oral Azacitidine ) Combination With Fulvestrant Postmenopausal Women ER+ , HER2- Metastatic Breast Cancer Who Have Progressed Aromatase Inhibitor .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Epigenetic Modifying Effects CC-486 ( Oral Azacitidine ) Combination With Fulvestrant</brief_title>
	<detailed_description>This Phase 2 , open-label , two-arm study assess efficacy safety combination fulvestrant CC-486 subject ER+ , HER2- metastatic breast cancer progress prior AI . Approximately 92 subject enrol assign randomly 1:1 ratio one two treatment arm : - Arm A : CC-486 300 mg fulvestrant 500 mg : 46 subject - Arm B : Fulvestrant 500 mg : 46 subject Each cycle 28 day . CC-486 administer orally dose 300 mg daily day 1-21 28-day cycle . Fulvestrant administer intramuscular ( IM ) injection dose 500 mg day 1 15 cycle 1 day 1 subsequent cycle . Safety evaluate independent data monitoring committee ( DMC ) total approximately 32 subject complete least 1 treatment cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Subject female â‰¥ 18 year age ( time signing informed consent form ) metastatic breast cancer amenable curative treatment surgery radiotherapy . Subject consider postmenopausal Subject histologically and/or cytologically confirm diagnosis estrogenreceptor positive breast cancer local laboratory ( base recently analyze biopsy ) . Subject human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer ( base recently analyze biopsy ) define negative situ hybridization test Immunohistochemistry ( IHC ) status 0 , 1+ 2+ . If IHC 2+ , negative situ hybridization ( FISH , CISH , SISH ) test require local laboratory test . Subject disease refractory AI Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Subject radiological document measurable disease ( ie , least one measureable lesion per Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.1 ) . If measurable disease present , least one predominantly lytic bone lesion must present Subject adequate organ function . Subject adequate bone marrow function . Subject receive &gt; 1 prior line chemotherapy metastatic setting Subject receive chemotherapy within 21 day prior randomization . Subject receive prior treatment fulvestrant . Subject previously treat azacitidine ( formulation ) , decitabine , hypomethylating agent . Subject history , current symptomatic brain metastasis . Subject severe renal impairment ( creatinine clearance &lt; 30 ml/min ) . Subject impaired ability swallow oral medication . Subject contraindication receive IM injection ( eg , bleed disorder , anticoagulant use ) . Subject significant active cardiac disease within previous 6 month include unstable angina angina require surgical medical intervention , significant cardiac arrhythmia , New York Heart Association ( NYHA ) class 3 4 congestive heart failure . Subject female Childbearing Potential [ define sexually mature woman ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oopherectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 12 consecutive month ( ie , menses time precede 12 consecutive month ) ] .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Her2 -</keyword>
	<keyword>ER+</keyword>
	<keyword>CC-486 ( ORAL AZACITIDINE )</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Oralazacitidine</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Epigenetics</keyword>
</DOC>